Job
Description
Position: Project Management
Report to: R&D Head
Location: Beijing
Language: Chinese & English
Accountabilities:
❒
Manage all CMC project
plans and timeline, including research pre-clinic and clinic stage CMC
projects, and working with financing department to manage RD budget
❒
Worked closely with internal
and external project team to make sure all project on time smoothly by
coordinating resources, regular tracking, weekly reporting to senior management
team etc.
❒
Manage risks and changes
in the project, and timely coordinate related resources to solve the problems
of the project;
❒
Responsible for the key
millstone review of the project and documentation review and filing;
❒
Coordinate the internal
and external partners of the project, assist the project team to select external
suppliers, and ensure the participation of all functional departments within
the company in the project;
❒
Other tasks that may
assigned by Supervisor or CEO
Qulifications:
❒ PH D or Master or BS in biological sciences, pharmaceuticals, medical sciences, or business management, finance, or related fields. Educational background in oversea as plus.
❒ Ph.D. 3+ or MS 5+ or BS 10+ years’ experience in project management in biotech or pharma industry; Familiar with biologic R&D process; Experience/knowledge in CMC development or toxicology or IND package preparation as a plus.
❒ Familiar with biotech industry policy, overseas study or working experience preferred;
❒ Excellent coordination and communication skills, multi-tasking ability and anti-pressure ability.
❒ Excellent teamwork skills and influence; A good team player
as well as a leader in cross function environment;
❒ Excellent in reading and writing level both in Chinese and
English。
TAYU-BIOTECH
Introduction:
TAYU Biotech group was established in
September 2016, which is committed to develop innovative immunotherapy drug in
China founded by Professor Chen Lieping who is a global famous immunologists
and oncologists.
Professor Chen Lieping is the world’s leading investigator in
the characterization of cell surface co-stimulatory and co-inhibitory molecules
that modulate immune responses. He is professor of immunobiology, of dermatology, and of medicine
(medical oncology) at Yale School of Medicine and director of the cancer
immunology program at the Yale Cancer Center. Professor Chen is the first scientist to
apply co-stimulation as a mean for cancer immunotherapy. His laboratory
discovered immune suppressive function of the B7-H1 (PD-L1)/PD-1 pathway in
cancer and first demonstrated using antibody to block this pathway to enhance
tumor immunity for the therapy of cancer. The anti-PD-1 and anti-PD-L1 has been
well recognized as the most safe and effective drugs for the therapy of cancer
so far.
With a
rich experienced R&D team, TAYU is developing anti-tumor drug including
immune checkpoint inhibitors, co-stimulus antibodies, dual specificity
antibodies and biomarker etc. TAYU group will strive to grow into a top
biopharmaceuticals group that covers research, transformation and manufacture
in the future.
For more
information please click www.tayubiotech.com
Contact information:
Address:
8-2 Dongdan Santiao, Dongcheng district, Beijing, China
Tel:
+86 10 67177097
E-mail:clara@tayubiotech.com